Results from the Evolut FX TAVR (Transcatheter Aortic Valve Replacement) Clinical Survey were presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & ...
Results from the Evolut FX TAVR (Transcatheter Aortic Valve Replacement) Clinical Survey were presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & ...
The US Food and Drug Administration has approved Medtronic's Evolut FX system for transcatheter aortic valve replacement (TAVR) in patients with symptomatic severe aortic stenosis at all risk levels.
DUBLIN, Aug. 24, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval of its newest-generation, ...
Medtronic’s newest generation Evolut FX transcatheter aortic valve replacement system (TAVR) significantly improved commissure alignment during TAVR procedures compared to earlier generations, ...
PHOENIX -- The newer generation Evolut transcatheter aortic valve replacement (TAVR) device improved on procedural and possibly safety characteristics, the TVT registry showed. The Evolut FX device ...
Medtronic today announced that FDA has approved the Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The system is the latest ...
Medtronic plc MDT recently gained FDA approval for its Evolut FX TAVR system. The Evolut FX system is Medtronic’s latest-generation, self-expanding transcatheter aortic valve replacement (TAVR) system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results